On January 3, 2018 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), ("Onxeo" or the "Company"), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, reported that its management team will attend the following key investor and partnering conferences in the first half of 2018 (Press release, Onxeo, JAN 3, 2018, View Source [SID1234522855]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor meetings during the JP Morgan Healthcare Conference 2018
January 8-11, 2018
San Francisco, US

ODDO BHF Forum
January 12, 2018
Lyon, France

BIO-Europe Spring
March 12-14, 2018
Amsterdam, The Netherlands

CM-CIC Market Solutions Forum by ESN
March 22-23, 2018
Paris, France

Portzamparc MidCap 2018 Conference
April 4-5, 2018
Paris, France

BIO International Convention
June 4-7, 2018
Boston, US

SG CIB Nice Conference 2018
June 7-8, 2018
Nice, France